[
    [
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)：前三季净利预增145%至175%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "净利",
                    "预增",
                    "145%",
                    "175%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：前三季净利预增145%至175%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业前三季盈利4.86亿元~5.46亿元，投资收益贡献近半利润",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盈利",
                    "投资收益",
                    "利润"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业前三季盈利4.86亿元~5.46亿元，投资收益贡献近半利润",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：前三季度预计净利润同比增长145.0%~175.0%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "净利润",
                    "同比增长",
                    "145.0%",
                    "175.0%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：前三季度预计净利润同比增长145.0%~175.0%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)预计前三季度归母净利润同比上升145%至175%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "归母净利润",
                    "同比上升",
                    "145%",
                    "175%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)预计前三季度归母净利润同比上升145%至175%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "新股前瞻丨加科思：王印祥离开贝达药业（300558.SZ）后的底气",
            "features": {
                "keywords": [
                    "加科思",
                    "王印祥",
                    "离开",
                    "贝达药业",
                    "底气"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "新股前瞻丨加科思：王印祥离开贝达药业（300558.SZ）后的底气",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业2020三季度业绩前瞻：板块分化明显 医疗服务等板块有序复苏",
            "features": {
                "keywords": [
                    "医药生物",
                    "2020",
                    "三季度",
                    "业绩",
                    "板块分化",
                    "医疗服务",
                    "复苏"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗服务"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业2020三季度业绩前瞻：板块分化明显 医疗服务等板块有序复苏",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]